| 1. |
- Johansson, Lovisa, et al.
(author)
-
Genetic variance in the adiponutrin gene family and childhood obesity.
- 2009
-
In: PLoS ONE. - : Public Library of Science (PLoS). - 1932-6203. ; 4:4
-
Journal article (peer-reviewed)abstract
- AIM: The adiponutrin gene family consists of five genes (PNPLA1-5) coding for proteins with both lipolytic and lipogenic properties. PNPLA3 has previously been associated with adult obesity. Here we investigated the possible association between genetic variants in these genes and childhood and adolescent obesity. METHODS/RESULTS: Polymorphisms in the five genes of the adiponutrin gene family were selected and genotyped using the Sequenom platform in a childhood and adolescent obesity case-control study. Six variants in PNPLA1 showed association with obesity (rs9380559, rs12212459, rs1467912, rs4713951, rs10947600, and rs12199580, p<0.05 after adjustment for age and gender). Three variants in PNPLA3 showed association with obesity before, but not after, adjustment for age and gender (rs139051, rs12483959, and rs2072907, p>0.05). When analyzing these SNPs in relation to phenotypes, two SNPs in the PNPLA3 gene showed association with insulin sensitivity (rs12483959: beta = -0.053, p = 0.016, and rs2072907: beta = -0.049, p = 0.024). No associations were seen for PNPLA2, PNPLA4, and PNPLA5. CONCLUSIONS: Genetic variation in the adiponutrin gene family does not seem to contribute strongly to obesity in children and adolescents. PNPLA1 exhibited a modest effect on obesity and PNPLA3 on insulin sensitivity. These data, however, require confirmation in other cohorts and ethnic groups.
|
|
| 2. |
|
|
| 3. |
- Demmelmaier, Ingrid, 1960-, et al.
(author)
-
Does exercise intensity matter for fatigue during (neo-)adjuvant cancer treatment? The Phys-Can randomized clinical trial
- 2021
-
In: Scandinavian Journal of Medicine and Science in Sports. - : Wiley. - 0905-7188 .- 1600-0838. ; 31:5, s. 1144-1159
-
Journal article (peer-reviewed)abstract
- Exercise during cancer treatment improves cancer-related fatigue (CRF), but the importance of exercise intensity for CRF is unclear. We compared the effects of high- vs low-to-moderate-intensity exercise with or without additional behavior change support (BCS) on CRF in patients undergoing (neo-)adjuvant cancer treatment. This was a multicenter, 2x2 factorial design randomized controlled trial (Clinical Trials NCT02473003) in Sweden. Participants recently diagnosed with breast (n = 457), prostate (n = 97) or colorectal (n = 23) cancer undergoing (neo-)adjuvant treatment were randomized to high intensity (n = 144), low-to-moderate intensity (n = 144), high intensity with BCS (n = 144) or low-to-moderate intensity with BCS (n = 145). The 6-month exercise intervention included supervised resistance training and home-based endurance training. CRF was assessed by Multidimensional Fatigue Inventory (MFI, five subscales score range 4-20), and Functional Assessment of Chronic Illness Therapy-Fatigue scale (FACIT-F, score range 0-52). Multiple linear regression for main factorial effects was performed according to intention-to-treat, with post-intervention CRF as primary endpoint. Overall, 577 participants (mean age 58.7 years) were randomized. Participants randomized to high- vs low-to-moderate-intensity exercise had lower physical fatigue (MFI Physical Fatigue subscale; mean difference −1.05 [95% CI: −1.85, −0.25]), but the difference was not clinically important (ie <2). We found no differences in other CRF dimensions and no effect of additional BCS. There were few minor adverse events. For CRF, patients undergoing (neo-)adjuvant treatment for breast, prostate or colorectal cancer can safely exercise at high- or low-to-moderate intensity, according to their own preferences. Additional BCS does not provide extra benefit for CRF in supervised, well-controlled exercise interventions.
|
|
| 4. |
|
|
| 5. |
- Johansson, Pernilla, et al.
(author)
-
Fältförsök med träskyddsmedel för klass AB. Delrapport nr 2. Resultat efter 5 års exponering. Nordic Wood projekt nr 98056
- 2001
-
Reports (peer-reviewed)abstract
- Since 1994 there are restrictions in Sweden on the use of chromium and arsenic containing wood preservatives. These preservatives are now in principle allowed for use in ground contact and water only. The use of chromium and arsenic free preservatives has increased and dominates the Swedish market for commodities above ground (Nordic wood preservation class AB). As the knowledge of the performance of these preservatives is limited, a field trial was set up in order to get more information about the durability in ground and above ground, discolouration by staining fungi, leaching, weathering and corrosion on fasteners in contact with the treated wood. Samples were treated according to class AB in commercial treating plants with the following preservatives: Basilit Bauholz KVD, Impralit KDS, Kemwood ACQ 1900, Tanalith E, Wolmanit CX-S and Wolmanit CX-8. Untreated spruce and heartwood of pine and larch were also included in the trial. In addition to testing according to EN 252 and ENV 12037 (lap-joint), both somewhat modified, testing was also carried out according to methods specially designed for this trial. After five years exposure the results show that: · No treated samples exposed above ground have yet been attacked and very few untreated samples only have been severely attacked by wood destroying fungi. There is thus some concern that the methods used, and in particular the lap-joint method, are not suitable for above ground testing in temperate climates. · The tests in ground indicate that with increasing copper content in the treated wood the better is the performance. · Heartwood of larch performs better than heartwood of pine in the in ground tests. On contrary, heartwood of pine shows better decay resistance than heartwood of larch in the above ground tests. · All samples are more or less attacked by bluestain fungi. Untreated samples are severely attacked. · Stainless steel has the best performance against corrosion. Wood treated with Kemwood ACQ 1900 and Wolmanit CX-8 seems to accelerate the corrosion of most other fastener materials. · The leaching of the chromium and arsenic free preservatives seems to be substantial whereas the leaching from CCA-treated references is little or moderate. For wood preservatives containing copper and an organic active ingredient, copper seems to be less susceptible to leaching then the organic component for which not only leaching but also chemical decomposition may take place.
|
|
| 6. |
- Johansson, Pernilla, et al.
(author)
-
Utveckling och validering av modeller för att prediktera mögelväxt i byggnader
- 2018
-
Reports (other academic/artistic)abstract
- In this project we have tested a mould model originally developed by Skanska (the m-model) and a method developed by RISE in Sweden (the GLC-method) on data from both laboratory and field measurements. The laboratory measurements had durations of a few months and were made in climate chambers at RISE; the field measurements were made in 12 buildings during 30 months. In both cases, temperature, relative humidity and mould growth was assessed on six different materials. The results were used to investigate if the m-model or the GLC-method could predict when there was mould growth. Both methods could differentiate between the (dry) cases without mould and the (moist) cases with mould. However, we could not find mould resistance parameters for the tested materials to be used with the m-model. This could be because the m-model cannot predict mould growth well enough, but it can also be because the types of measurements that we have made have relative large uncertainties in relative humidity. Isotheral calorimetry was also investigated as an interesting method to study how drying affects the activity of mould fungi.
|
|
| 7. |
- Johansson, Roger, et al.
(author)
-
Om forskningscirkeln
- 2019
-
In: Tjänstelogik i välfärden. En modell för samskapande mellan professionella med barnet i fokus. - 9789144120577 ; , s. 153-160
-
Book chapter (other academic/artistic)
|
|
| 8. |
- Kindstedt, Elin, et al.
(author)
-
Association between marginal jawbone loss and the onset of rheumatoid arhtritis and relationship to plasma levels of RANKL
- 2018
-
In: Arthritis & Rheumatology. - : Wiley-Blackwell. - 2326-5191 .- 2326-5205. ; 70:4, s. 508-515
-
Journal article (peer-reviewed)abstract
- Objective: To investigate whether periodontitis, characterized by marginal jawbone loss, precedes the onset of symptoms of rheumatoid arthritis (RA), and to analyze plasma levels of RANKL (a cytokine that is crucial for bone resorption) and anti–citrullinated peptide antibodies (ACPAs) in presymptomatic individuals compared with matched referent controls.Methods: Marginal jawbone loss was measured on dental radiographs of the premolar/molar regions in the jaws in 176 subjects, 93 of whom subsequently developed RA. Among these participating subjects, 46 had documented radiographs predating symptom onset, and 45 cases could be matched to controls, according to sex, age, and smoking status. Plasma RANKL concentrations were analyzed using enzyme‐linked immunosorbent assay. A receiver operating characteristic curve was used to define the cutoff value for RANKL positivity.Results: Bone loss was significantly greater in presymptomatic subjects classified as never smokers compared with that in controls, and increasing levels of bone loss were associated with a higher risk of the subsequent development of RA (hazard ratio 1.03, 95% confidence interval 1.01–1.05). No association between jawbone loss and RA was observed in smokers. A significantly greater extent of marginal jawbone loss was detected in RANKL‐positive presymptomatic subjects, and even more pronounced jawbone loss was observed in those who were positive for both RANKL and ACPA.Conclusion: Marginal jawbone loss preceded the clinical onset of RA symptoms, but this was observed only in nonsmokers. Moreover, marginal jawbone loss was significantly greater in RANKL‐positive presymptomatic subjects compared with RANKL‐negative presymptomatic subjects and was highest in presymptomatic subjects positive for both ACPA and RANKL.
|
|
| 9. |
- Kindstedt, Elin, et al.
(author)
-
Marginal jawbone loss is associated with onset of rheumatoid arthritis and is related to plasma level of receptor activator of nuclear factor kappa-B-ligand (RANKL)
-
Other publication (other academic/artistic)abstract
- OBJECTIVES: We investigated whether periodontitis, displayed as marginal jawbone loss, preceded onset of symptoms of RA. Furthermore, we analysed plasma levels of receptor activator of nuclear factor kappa-B (RANKL), a cytokine crucial for bone resorption and of anti-citrullinated peptide antibodies (ACPA) in pre-symptomatic individuals compared with controls.METHODS: Marginal jawbone levels were measured on dental radiographs from the premolar/molar regions of the jaws of 176 subjects of whom 93 had developed RA. Of these, 47 had documented radiographs predating symptom onset and for 45 of them sex, age and smoking status referents could be matched. The plasma RANKL concentrations were analysed using ELISA. The receiver operating characteristic curve was used to define the cut-off value.RESULTS: Compared with matched referents, bone loss was significantly higher in never-smoking, pre-symptomatic subjects and increasing levels of bone loss was associated with higher risk to develop subsequent RA (hazard ratio=1.06, 95%CI 1.01, 1.11). No association was found in smokers. In the pre- symptomatic RANKL-positive individuals a significantly higher extent of marginal jawbone loss, and those who were both RANKL- and ACPA positive displayed an even more pronounced jawbone loss.CONCLUSIONS: Marginal jawbone loss preceded clinical onset of symptoms of RA but the difference was only manifested in non-smokers. Moreover, pre- symptomatic RA-individuals, who were RANKL positive, displayed a significantly higher degree of marginal jawbone loss, particularly in ACPA positive individuals.
|
|
| 10. |
- Kindstedt, Elin, et al.
(author)
-
Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) and Marginal Jawbone Loss Predates the Onset of Rheumatoid Arthritis
- 2017
-
In: Arthritis & Rheumatology. - : Wiley-Blackwell. - 2326-5191 .- 2326-5205. ; 69
-
Journal article (other academic/artistic)abstract
- Background/Purpose: Previous studies have shown a higher incidence of alveolar bone loss in patients with rheumatoid arthritis (RA) and that patients with periodontitis are at a greater risk for developing RA. Periodontitis, displayed as marginal jawbone loss was analysed in individuals prior to symptom onset of RA and related to plasma levels of receptor activator of nuclear factor kappa-B (RANKL), a cytokine crucial for bone resorption. Methods: A case-control study performed within the Medical Biobank of Northern Sweden included 232 pre-symptomatic individuals with blood samples donated before symptom onset and 194 controls. A questionnaire on self-assed dental status and smoking status was retrieved. Dental radiographs to evaluate marginal jawbone levels were available from 93 pre-symptomatic individuals (mean age; 56.8 95%CI55.9, 57.7 years and pre-dating time; -5.3 95%CI -12.2, -0.2, 74.2% females) and 83 controls (mean age; 55.5 95%CI54.6, 56.5, 73.5% females) . Of these individuals 45 had radiograph documentations prior to development of RA symptoms and to whom sex, age and smoking status could be matched among the controls. Plasma were analysed for RANKL (BioVendor, Karasek, Czech Republic), and anti-citrullinated peptide antibodies (ACPA) (anti-CCP2 test, Eurodiagnostics, Sweden) from similar time points. Results: Compared to matched controls, total bone loss was significantly higher in never-smokers who developed RA but not in smokers and increasing levels on total jawbone loss was associated with a significantly higher odds to be diagnosed with RA later (OR=1.06, 95%CI 1.01, 1.11). Regardless of smoking status, the number of unaffected teeth did not differ significantly between those who were subsequently diagnosed with RA and their matched controls. In the pre-symptomatic individuals RANKL positive individuals had significantly higher extent of marginal jawbone loss, which was further increased in ACPA positive individuals. Previously documented association between smoking and ageing and marginal jawbone loss was verified. Conclusion: Marginal jawbone loss preceded onset of symptoms of RA but the difference was only manifested in non-smokers. Moreover, marginal jawbone loss and plasma RANKL levels were related in the pre-symptomatic individuals particularly in ACPA positive individuals.
|
|
